Volume 38 Issue 9, 1 September 2020

Single-cell analysis sheds light on immune response to COVID-19 infection, enables the rapid discovery of antibody leads, and points to ways to get ahead of future pandemics.

The interaction between patents and FDA’s De Novo and 510(k) regulatory pathways has the potential to threaten follow-on innovation for medical devices.

Recent patents related to new biomarkers and methods of transcriptomic data analysis and integration.

Viscoplastic electronic devices adapt as nerves enlarge in growing animals.

The activity of adenine or cytosine base editors at specific target nucleotides is predicted computationally.

High contiguity human genomes can be assembled de novo in 6 h using nanopore long-read sequences and the Shasta toolkit.

A sex-distorter gene drive causes population collapse in the malaria mosquito.

Markers that distinguish pancreatic and hepatic progenitors improve stem-cell differentiation to pancreatic β cells.

A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus.

A full species classification is built for all publicly available bacterial and archaeal genomes.

The biological activities of >800,000 small molecules are represented within a uniform framework.

A new workshop brings together under-represented participants to gain experience working in diverse teams, identifying problems worth solving, and learning evidence-based entrepreneurship approaches.

Recent moves of note in and around the biotech and pharma industries.